CTVIF yields 23.97% · PFE yields 6.13%● Live data
📍 CTVIF pulled ahead of the other in Year 1
Combined, CTVIF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CTVIF + PFE for your $10,000?
China Travel International Investment Hong Kong Limited, an investment holding company, provides travel and tourism services. Its Tourist Attraction and Related Operations segment operates theme parks, scenic spots, cable car systems, skiing facilities, hot spring resorts, and other resorts, as well as engages in arts performance and tourism property development activities in Mainland China. The company's Travel Agency, Travel Document, and Related Operations segment provides travel agency, travel document, and related services in Hong Kong, Mainland China, South East Asia, Oceania, the United States, and countries in the European Union. Its Hotel Operations segment offers hotel accommodation, and food and beverage services in Hong Kong, Macau, and Mainland China. The company's Passenger Transportation Operations segment provides cross-border transportation services to individuals travelling between Hong Kong, Macau, and Mainland China; and vehicle and vessel rental and charter operations in Hong Kong, Macau, and Mainland China. It also operates golf clubs; trades in computer equipment and provides computer services; and offers travel and air ticketing agency, entry permit handling agency, fuel supply, ship repairing, and logistics and courier services. In addition, the company is involved in property investment; software system development; and shipping and shipping management activities, as well as conference and exhibition operations. The company was incorporated in 1992 and is based in Central, Hong Kong. China Travel International Investment Hong Kong Limited is a subsidiary of China Travel Service (Holdings) Hong Kong Limited.
Full CTVIF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.